Our mission is to make the most meaningful difference to health through great medicines that bring benefit for patients and add value for our stakeholders and society. The diagram above illustrates the strategic framework which defines the direction and shape of the Group to deliver our mission.
We believe that the most value-creating strategy for AstraZeneca is to be a focused, integrated, innovation-driven, global, prescription-based biopharmaceutical business:
- biopharmaceutical in that we will develop both chemical (small molecule) and biological (large molecule) medicines
- focused in that we will continue to be selective about those areas of the pharmaceutical industry in which we choose to compete, targeting those product categories where medical innovation or brand equity will continue to enable us to make acceptable levels of return on our investments
- integrated in that we believe the best way to capture value within this industry is to span the full value chain of discovery, development and commercialisation, while continuing to work with partners and outsourcing to capture operational efficiencies
- innovation-driven in that we believe our technology base will continue to deliver innovative products that will benefit patients and for which payers will pay
- global in that we believe we have the ability to meet healthcare needs in both established and emerging markets efficiently and effectively.
We believe that there continue to be opportunities to create value for those who invest in pharmaceutical innovation, and that AstraZeneca has the skills and capabilities to take advantage of these opportunities and turn them into long-term value through the research, development and marketing of medicines. For us, this is the core of our commitment to our stakeholders and society. Successful pharmaceutical innovation, delivered responsibly, brings benefits to patients, creates sustainable value for shareholders and contributes to the economic and social welfare of the communities we serve.